nature

当前位置: Nature » 免疫学 » 正文

Nature:向寨卡/登革热疫苗迈进

摘要 : Félix Rey及同事表明,从感染登革热病毒的患者身上得到的一种单克隆抗体亚群可与寨卡病毒E蛋白结合,阻止寨卡病毒感染。

 Félix Rey及同事表明,从感染登革热病毒的患者身上得到的一种单克隆抗体亚群可与寨卡病毒E蛋白结合,阻止寨卡病毒感染。寨卡病毒E蛋白是一种协助病毒进入的黄病毒包膜糖蛋白。这两种抗体与寨卡病毒囊膜蛋白结合的结构数据定义了中和表位的范围、组成和化学性质,并识别出抗体交叉反应的结构基础。这一研究表明,以寨卡与登革热病毒的免疫复合物为线索,也许能设计可产生强效交叉中和抗体,以抵抗两种病原体的通用疫苗。

原文链接:

Structural basis of potent Zika–dengue virus antibody cross-neutralization

原文摘要:

Zika virus is a member of the Flavivirus genus that had not been associated with severe disease in humans until the recent outbreaks, when it was linked to microcephaly in newborns in Brazil and to Guillain–Barré syndrome in adults in French Polynesia. Zika virus is related to dengue virus, and here we report that a subset of antibodies targeting a conformational epitope isolated from patients with dengue virus also potently neutralize Zika virus. The crystal structure of two of these antibodies in complex with the envelope protein of Zika virus reveals the details of a conserved epitope, which is also the site of interaction of the envelope protein dimer with the precursor membrane (prM) protein during virus maturation. Comparison of the Zika and dengue virus immunocomplexes provides a lead for rational, epitope-focused design of a universal vaccine capable of eliciting potent cross-neutralizing antibodies to protect simultaneously against both Zika and dengue virus infections.

来源: Nature 浏览次数:1

热门文章TOP

RSS订阅 - 填写您的邮件地址,订阅我们的精彩内容: - 网站地图
网站联系电话:020-87540820 备案号:粤ICP备11050685号-8 增值电信业务经营许可证:粤B2-20120479
©2011-2015 生物帮 All rights reserved.